Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Conditions: B-ALL; B-cell Non Hodgkin Lymphoma; DLBCL Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: CD22 CAR Sponsor: Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials